Abstract:Background: Baicalin is the main bioactive constitute of the dried roots of Scutellaria baicalensis and possesses various biological activities. However, the poor water solubility and low oral bioavailability limit its efficacy. Objective: The present study was conducted to enhance the dissolution and oral bioavailability of baicalin (BA) through a novel mesoporous carbon nanopowder (MCN) drug carrier. Materials and methods: Solid dispersions (SDs) of BA with MCN were prepared using a solvent evaporation method. The physical state of the formulations was investigated using SEM, differential scanning calorimetry (DSC) and powder X-ray diffraction (XRD). The pharmaceutical performance of pure BA, physical mixture (PM) and SDs was evaluated by performing an in-vitro dissolution test. The pharmacokinetic studies were conducted in SD rats and the analysis of the biological samples was performed on an Acquity UPLC-MS system. The intestinal and renal toxicity test of MCN was also evaluated. Results: The drug release profile indicated that the BA dissolution rate from SDs with a BA/MCN ratio of 1:6 greatly increased in comparison with that of the pure crystalline drug. Furthermore, a pharmacokinetic analysis in rats showed that the BA area under the concentration-time curve for SDs of MCN/BA was 1.83 times larger than that of pure BA. In comparison with the pure drug, the MCN-BA system significantly shortened the time to Tmax and generated higher Cmax. There was no intestinal and renal toxicity of MCN. Conclusion: These results indicated that the oral bioavailability of BA was remarkably improved by the MCN carrier. Additionally, intestinal toxicity test showed that MCN produced no toxicity in the gastrointestinal tract. Our results show that MCN-based SDs could be used to enhance the bioavailability of drugs with poor water solubility. Summary: The drug release profile indicated that the BA dissolution rate from SDs with a BA/MCN ratio of 1:6 greatly increased in comparison with that of the pure crystalline drug.Furthermore, a pharmacokinetic analysis in rats showed that the BA area under the concentration-time curve for SDs of MCN/BA was 1.83 times larger than that of pure BA.In comparison with the pure drug, the MCN-BA system significantly shortened the time to Tmax and generated higher CmaxAbbreviations used: BA: baicalin, MCN: mesoporous carbon nanopowder, SDs: solid dispersions, SEM: scanning electron microscopy, DSC: differential scanning calorimetry, XRD: powder X-ray diffraction, HPLC: high-performance liquid chromatography, PM: physical mixture, S.D.: standard deviation, ANOVA: analysis of variance, RSD: relative standard deviation, ESI: electrospray ionization, IS: internal standard, MRM: multiple reaction monitoring.

Nanostructured Lipid Carriers for Oral Delivery of Baicalin: in Vitro and in Vivo Evaluation

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo

Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design

Long-circulating nanoliposomes (LCNs) sustained delivery of baicalein (BAI) with desired oral bioavailability in vivo

Nanostructured Lipid Carriers As a Delivery System of Biochanin A

In Vitroandin Vivostudy of Baicalin-loaded Mixed Micelles for Oral Delivery

Characterization and Evaluation in Vivo of Baicalin-Nanocrystals Prepared by an Ultrasonic-Homogenization-fluid Bed Drying Method

Preparation, optimization, characterization and in vitro release of baicalein-solubilizing glycyrrhizic acid nano-micelles

Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion

Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting.

Nanoparticle-Mediated Dual Targeting: An Approach for Enhanced Baicalin Delivery to the Liver

Baicalin-berberine complex nanocrystals orally promote the co-absorption of two components

Preparation, Characterization, Pharmacokinetics and Biodistribution of Baicalin-Loaded Liposome on Cerebral Ischemia-Reperfusion after i.v. Administration in Rats

Preparation of Baicalin Liposomes Using Microfluidic Technology and Evaluation of Their Antitumor Activity by a Zebrafish Model

Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats

Trimethyl chitosan nanoparticles for ocular baicalein delivery: Preparation, optimization, in vitro evaluation, in vivo pharmacokinetic study and molecular dynamics simulation

Preparation and evaluation of Baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB

Study on Encapsulation Efficiency and in Vitro Release of Baicalin Liposomes

PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A.

Pharmacokinetics and Bioavailability Enhancement of Baicalin: A Review